JEMPERLI demonstrated efficacy across dMMR recurrent or advanced solid tumors1

Clinically meaningful responses achieved across patients with dMMR recurrent or advanced solid tumors1,2

GARNET Cohort A1+F overall response rate
GARNET Cohort A1+F duration of response
  • Median follow-up for duration of response was 17.5 months measured from time of first response

The efficacy of JEMPERLI was investigated in a global, nonrandomized, multicenter, multiple cohort, open-label study of 209 patients with dMMR recurrent or advanced solid tumors who had progressed following systemic therapy and had no satisfactory alternative treatment options.* Patients received JEMPERLI 500 mg via intravenous infusion every 3 weeks for 4 doses, followed by 1000 mg every 6 weeks until disease progression or unacceptable toxicity.

CI=confidence interval; CR=complete response; dMMR=mismatch repair deficient; ORR=overall response rate; PR=partial response.

  • * Patients with dMMR endometrial cancer must have progressed on or after treatment with a platinum-containing regimen. Patients with dMMR colorectal cancer must have progressed after or been intolerant to a fluoropyrimidine, oxaliplatin, and irinotecan.1

Response to JEMPERLI was observed in a variety of dMMR tumor types1

  • Endometrial cancer (n=46/103)
  • Colorectal cancer (n=25/69)
  • Small intestinal cancer (n=4/12)
  • Gastric cancers (n=3/8)
  • Biliary neoplasm (n=2/2)
  • Liver cancer (n=1/2)
  • Ovarian cancer (n=1/2)
  • Adrenal cortical (n=1/1)
  • Breast cancer (n=1/1)
  • Malignant neoplasm of the female genitals (n=1/1)
  • Pleural (n=1/1)
  • Unknown origin (n=1/1)
  • Includes patients with a partial or complete response.

Safety profile and tolerability of JEMPERLI were evaluated in patients with dMMR recurrent or advanced solid tumors (N=267)1

Blue light bulb icon

9% of patients permanently discontinued therapy due to adverse reactions

  • The most common adverse reaction (≥1%) leading to discontinuation was increased alanine aminotransferase (1.1%)
  • The most common adverse reactions (≥20%) were fatigue/asthenia, anemia, diarrhea, and nausea
  • Serious adverse reactions occurred in 34% of patients receiving JEMPERLI, including (>2% of patients) abdominal pain (3.7%), sepsis (2.6%), and acute kidney injury (2.2%)
  • Fatal adverse reaction due to respiratory failure occurred in 1 patient who received JEMPERLI

After initial 4 doses, 6-week dosing with JEMPERLI1

JEMPERLI offers a fixed-dose regimen every 3 weeks for the initial 4 doses, then every 6 weeks.

  • Three weeks between Dose 4 and Dose 5.
Brochure icon

JEMPERLI has
other indications

EXPLORE INDICATIONS

Icon: JEMPERLI (dostarlimab-gxly) Mechanism of Action

JEMPERLI activates
T cells

DISCOVER HOW JEMPERLI WORKS

Icon: JEMPERLI (dostarlimab-gxly) Support

Learn about support for JEMPERLI at every step

SEE REIMBURSEMENT SUPPORT